ARMP Stock News & Analysis | Latest Updates

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(ARMP) LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of...

September 4, 2025Corporate

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

ARMP

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"),...

August 12, 2025Earnings

HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $9

ARMP

May 19, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session

ARMP

May 19, 2025

Armata Pharmaceuticals Announced Positive Topline Results From Its Phase 1B/2A Disarm Trial Which Evaluated Ap-sa02, A Novel Intravenous Administered Multi-phage Therapeutic For The Treatment Of Staphylococcus Aureus Bacteremia, In The Intent-to-treat Pop

ARMP

May 19, 2025

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

ARMP

May 14, 2025

Armata Secures $4.65M DoD Funding To Advance AP-SA02 Trial For Staph Bacteremia, Topline Data Expected Q2 2025

ARMP

May 1, 2025

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

ARMP

March 20, 2025

Armata Enters $10M Secured Credit Agreement With Innoviva Strategic Opportunities LLC

ARMP

March 12, 2025

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

ARMP

December 19, 2024

Armata Pharmaceuticals Announced Topline Results From Its Phase 2 Tailwind Trial Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Non-cystic Fibrosis Bronchiectasis Patients

ARMP

December 19, 2024

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

ARMP

November 14, 2024

ARMP News

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Raises Price Target to $9

12 Health Care Stocks Moving In Monday's Pre-Market Session

Armata Pharmaceuticals Announced Positive Topline Results From Its Phase 1B/2A Disarm Trial Which Evaluated Ap-sa02, A Novel Intravenous Administered Multi-phage Therapeutic For The Treatment Of Staphylococcus Aureus Bacteremia, In The Intent-to-treat Pop

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

Armata Secures $4.65M DoD Funding To Advance AP-SA02 Trial For Staph Bacteremia, Topline Data Expected Q2 2025

Armata Pharmaceuticals Q4 2024 GAAP EPS $(0.23) Beats $(0.35) Estimate, Sales $1.24M Miss $1.56M Estimate

Armata Enters $10M Secured Credit Agreement With Innoviva Strategic Opportunities LLC

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

Armata Pharmaceuticals Announced Topline Results From Its Phase 2 Tailwind Trial Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Non-cystic Fibrosis Bronchiectasis Patients

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target